 | • レポートコード：20QY06-05931 • 出版社/出版日：QYResearch / 2020年6月1日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、147ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、脂質異常症薬のグローバル市場について種類別（スタチン、コレステロール吸収阻害剤、高脂血症注射剤）、用途別（病院、診療所、医療研究所、ドラッグストア、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・脂質異常症薬市場の概要 ・世界の主要地域別脂質異常症薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の脂質異常症薬市場規模2015-2026：種類別（スタチン、コレステロール吸収阻害剤、高脂血症注射剤） ・世界の脂質異常症薬市場規模2015-2026：用途別（病院、診療所、医療研究所、ドラッグストア、その他） ・脂質異常症薬の北米市場規模2015-2020 ・脂質異常症薬のヨーロッパ市場規模2015-2020 ・脂質異常症薬の中国市場規模2015-2020 ・脂質異常症薬の日本市場規模2015-2020 ・脂質異常症薬の東南アジア市場規模2015-2020 ・脂質異常症薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （AstraZeneca、Merck、Pfizer、Sanofi、Alnylam Pharmaceuticals、Amarin Corporation、Amgen、Bristol-Myers Squibb、Catabasis Pharmaceuticals、Cerenis、Cipla、CJ HealthCare、CKD Bio、Daewoong Pharmaceutical、Daiichi Sankyo、Eli Lilly、Esperion Therapeutics、GlaxoSmithKline、JW Pharmaceuticals、Kadmon Pharmaceuticals、Lupin Pharmaceuticals） ・脂質異常症薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・脂質異常症薬の市場動向・機会・課題 ・調査の結論 |
Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual.
The increasing risk of cardiovascular disease (CVDs) is the primary driver for the market’s growth. Elevated cholesterol levels account for nearly one-third of the total ischemic heart diseases and persist as a substantial cause of ischemic heart diseases and strokes in emerging countries such as India and China. Thus, the cardiovascular risk management guidelines set by authorities such as the American College of Cardiology and American Heart Association acknowledge the decreasing the blood cholesterol as a prime factor in cutting down on the cardiovascular risks. This, in turn, drives the cholesterol maintaining drugs to avoid CVDs risk and boosting the sales of the drugs market.
Market Analysis and Insights: Global Dyslipidemia Drugs Market
The global Dyslipidemia Drugs market was valued at US$ 18790 million in 2019 and will reach US$ 32440 million by the end of 2026, growing at a CAGR of 8.0% during 2020-2026.
Global Dyslipidemia Drugs Scope and Market Size
The global Dyslipidemia Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Dyslipidemia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Dyslipidemia Drugs market is segmented into
Statins
Cholesterol absorption inhibitors
Dyslipidemia injectable
Segment by Application, the Dyslipidemia Drugs market is segmented into
Hospitals and Clinics
Medical Laboratories
Drug Stores
Others
The Dyslipidemia Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Dyslipidemia Drugs market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Dyslipidemia Drugs Market Share Analysis
Dyslipidemia Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Dyslipidemia Drugs business, the date to enter into the Dyslipidemia Drugs market, Dyslipidemia Drugs product introduction, recent developments, etc.
The major vendors covered:
AstraZeneca
Merck
Pfizer
Sanofi
Alnylam Pharmaceuticals
Amarin Corporation
Amgen
Bristol-Myers Squibb
Catabasis Pharmaceuticals
Cerenis
Cipla
CJ HealthCare
CKD Bio
Daewoong Pharmaceutical
Daiichi Sankyo
Eli Lilly
Esperion Therapeutics
GlaxoSmithKline
JW Pharmaceuticals
Kadmon Pharmaceuticals
Lupin Pharmaceuticals
Table of Contents
1 Dyslipidemia Drugs Market Overview
1.1 Dyslipidemia Drugs Product Scope
1.2 Dyslipidemia Drugs Segment by Type
1.2.1 Global Dyslipidemia Drugs Sales by Type (2020-2026)
1.2.2 Statins
1.2.3 Cholesterol absorption inhibitors
1.2.4 Dyslipidemia injectable
1.3 Dyslipidemia Drugs Segment by Application
1.3.1 Global Dyslipidemia Drugs Sales Comparison by Application (2020-2026)
1.3.2 Hospitals and Clinics
1.3.3 Medical Laboratories
1.3.4 Drug Stores
1.3.5 Others
1.4 Dyslipidemia Drugs Market Estimates and Forecasts (2015-2026)
1.4.1 Global Dyslipidemia Drugs Sales Growth Rate (2015-2026)
1.4.2 Global Dyslipidemia Drugs Revenue and Growth Rate (2015-2026)
1.4.3 Global Dyslipidemia Drugs Price Trends (2015-2026)
2 Dyslipidemia Drugs Estimate and Forecast by Region
2.1 Global Dyslipidemia Drugs Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Dyslipidemia Drugs Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Dyslipidemia Drugs Sales Market Share by Region (2015-2020)
2.2.2 Global Dyslipidemia Drugs Revenue Market Share by Region (2015-2020)
2.3 Global Dyslipidemia Drugs Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Dyslipidemia Drugs Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Dyslipidemia Drugs Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Dyslipidemia Drugs Estimates and Projections (2015-2026)
2.4.2 Europe Dyslipidemia Drugs Estimates and Projections (2015-2026)
2.4.3 China Dyslipidemia Drugs Estimates and Projections (2015-2026)
2.4.4 Japan Dyslipidemia Drugs Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Dyslipidemia Drugs Estimates and Projections (2015-2026)
2.4.6 India Dyslipidemia Drugs Estimates and Projections (2015-2026)
3 Global Dyslipidemia Drugs Competition Landscape by Players
3.1 Global Top Dyslipidemia Drugs Players by Sales (2015-2020)
3.2 Global Top Dyslipidemia Drugs Players by Revenue (2015-2020)
3.3 Global Dyslipidemia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dyslipidemia Drugs as of 2019)
3.4 Global Dyslipidemia Drugs Average Price by Company (2015-2020)
3.5 Manufacturers Dyslipidemia Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Dyslipidemia Drugs Players (Opinion Leaders)
4 Global Dyslipidemia Drugs Market Size by Type
4.1 Global Dyslipidemia Drugs Historic Market Review by Type (2015-2020)
4.1.1 Global Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
4.1.2 Global Dyslipidemia Drugs Revenue Market Share by Type (2015-2020)
4.1.3 Global Dyslipidemia Drugs Price by Type (2014-2020)
4.2 Global Dyslipidemia Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Dyslipidemia Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Dyslipidemia Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Global Dyslipidemia Drugs Price Forecast by Type (2021-2026)
5 Global Dyslipidemia Drugs Market Size by Application
5.1 Global Dyslipidemia Drugs Historic Market Review by Application (2015-2020)
5.1.1 Global Dyslipidemia Drugs Sales Market Share by Application (2015-2020)
5.1.2 Global Dyslipidemia Drugs Revenue Market Share by Application (2015-2020)
5.1.3 Global Dyslipidemia Drugs Price by Application (2015-2020)
5.2 Global Dyslipidemia Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Dyslipidemia Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Dyslipidemia Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Dyslipidemia Drugs Price Forecast by Application (2021-2026)
3 North America Dyslipidemia Drugs Market Facts & Figures
3.2 North America Dyslipidemia Drugs Sales Market Share by Company (2015-2020)
3.3 North America Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
3.4 North America Dyslipidemia Drugs Sales Market Share by Application (2015-2020)
4 Europe Dyslipidemia Drugs Market Facts & Figures
4.2 Europe Dyslipidemia Drugs Sales Market Share by Company (2015-2020)
4.3 Europe Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
4.4 Europe Dyslipidemia Drugs Sales Market Share by Application (2015-2020)
5 China Dyslipidemia Drugs Market Facts & Figures
5.2 China Dyslipidemia Drugs Sales Market Share by Company (2015-2020)
5.3 China Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
5.4 China Dyslipidemia Drugs Sales Market Share by Application (2015-2020)
6 Japan Dyslipidemia Drugs Market Facts & Figures
6.2 Japan Dyslipidemia Drugs Sales Market Share by Company (2015-2020)
6.3 Japan Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
6.4 Japan Dyslipidemia Drugs Sales Market Share by Application (2015-2020)
7 Southeast Asia Dyslipidemia Drugs Market Facts & Figures
7.2 Southeast Asia Dyslipidemia Drugs Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Dyslipidemia Drugs Sales Market Share by Application (2015-2020)
8 India Dyslipidemia Drugs Market Facts & Figures
8.2 India Dyslipidemia Drugs Sales Market Share by Company (2015-2020)
8.3 India Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
8.4 India Dyslipidemia Drugs Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Dyslipidemia Drugs Business
12.1 AstraZeneca
12.1.1 AstraZeneca Dyslipidemia Drugs Corporation Information
12.1.2 AstraZeneca Dyslipidemia Drugs Business Overview and Total Revenue
12.1.3 AstraZeneca Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.1.4 AstraZeneca Dyslipidemia Drugs Products Offered
12.1.5 AstraZeneca Recent Development
12.2 Merck
12.2.1 Merck Dyslipidemia Drugs Corporation Information
12.2.2 Merck Dyslipidemia Drugs Business Overview and Total Revenue
12.2.3 Merck Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Merck Dyslipidemia Drugs Products Offered
12.2.5 Merck Recent Development
12.3 Pfizer
12.3.1 Pfizer Dyslipidemia Drugs Corporation Information
12.3.2 Pfizer Dyslipidemia Drugs Business Overview and Total Revenue
12.3.3 Pfizer Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Pfizer Dyslipidemia Drugs Products Offered
12.3.5 Pfizer Recent Development
12.4 Sanofi
12.4.1 Sanofi Dyslipidemia Drugs Corporation Information
12.4.2 Sanofi Dyslipidemia Drugs Business Overview and Total Revenue
12.4.3 Sanofi Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Sanofi Dyslipidemia Drugs Products Offered
12.4.5 Sanofi Recent Development
12.5 Alnylam Pharmaceuticals
12.5.1 Alnylam Pharmaceuticals Dyslipidemia Drugs Corporation Information
12.5.2 Alnylam Pharmaceuticals Dyslipidemia Drugs Business Overview and Total Revenue
12.5.3 Alnylam Pharmaceuticals Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Alnylam Pharmaceuticals Dyslipidemia Drugs Products Offered
12.5.5 Alnylam Pharmaceuticals Recent Development
12.6 Amarin Corporation
12.6.1 Amarin Corporation Dyslipidemia Drugs Corporation Information
12.6.2 Amarin Corporation Dyslipidemia Drugs Business Overview and Total Revenue
12.6.3 Amarin Corporation Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Amarin Corporation Dyslipidemia Drugs Products Offered
12.6.5 Amarin Corporation Recent Development
12.7 Amgen
12.7.1 Amgen Dyslipidemia Drugs Corporation Information
12.7.2 Amgen Dyslipidemia Drugs Business Overview and Total Revenue
12.7.3 Amgen Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Amgen Dyslipidemia Drugs Products Offered
12.7.5 Amgen Recent Development
12.8 Bristol-Myers Squibb
12.8.1 Bristol-Myers Squibb Dyslipidemia Drugs Corporation Information
12.8.2 Bristol-Myers Squibb Dyslipidemia Drugs Business Overview and Total Revenue
12.8.3 Bristol-Myers Squibb Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Bristol-Myers Squibb Dyslipidemia Drugs Products Offered
12.8.5 Bristol-Myers Squibb Recent Development
12.9 Catabasis Pharmaceuticals
12.9.1 Catabasis Pharmaceuticals Dyslipidemia Drugs Corporation Information
12.9.2 Catabasis Pharmaceuticals Dyslipidemia Drugs Business Overview and Total Revenue
12.9.3 Catabasis Pharmaceuticals Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Catabasis Pharmaceuticals Dyslipidemia Drugs Products Offered
12.9.5 Catabasis Pharmaceuticals Recent Development
12.10 Cerenis
12.10.1 Cerenis Dyslipidemia Drugs Corporation Information
12.10.2 Cerenis Dyslipidemia Drugs Business Overview and Total Revenue
12.10.3 Cerenis Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Cerenis Dyslipidemia Drugs Products Offered
12.10.5 Cerenis Recent Development
12.11 Cipla
12.11.1 Cipla Dyslipidemia Drugs Corporation Information
12.11.2 Cipla Dyslipidemia Drugs Business Overview and Total Revenue
12.11.3 Cipla Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Cipla Dyslipidemia Drugs Products Offered
12.11.5 Cipla Recent Development
12.12 CJ HealthCare
12.12.1 CJ HealthCare Dyslipidemia Drugs Corporation Information
12.12.2 CJ HealthCare Dyslipidemia Drugs Business Overview and Total Revenue
12.12.3 CJ HealthCare Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.12.4 CJ HealthCare Dyslipidemia Drugs Products Offered
12.12.5 CJ HealthCare Recent Development
12.13 CKD Bio
12.13.1 CKD Bio Dyslipidemia Drugs Corporation Information
12.13.2 CKD Bio Dyslipidemia Drugs Business Overview and Total Revenue
12.13.3 CKD Bio Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.13.4 CKD Bio Dyslipidemia Drugs Products Offered
12.13.5 CKD Bio Recent Development
12.14 Daewoong Pharmaceutical
12.14.1 Daewoong Pharmaceutical Dyslipidemia Drugs Corporation Information
12.14.2 Daewoong Pharmaceutical Dyslipidemia Drugs Business Overview and Total Revenue
12.14.3 Daewoong Pharmaceutical Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Daewoong Pharmaceutical Dyslipidemia Drugs Products Offered
12.14.5 Daewoong Pharmaceutical Recent Development
12.15 Daiichi Sankyo
12.15.1 Daiichi Sankyo Dyslipidemia Drugs Corporation Information
12.15.2 Daiichi Sankyo Dyslipidemia Drugs Business Overview and Total Revenue
12.15.3 Daiichi Sankyo Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Daiichi Sankyo Dyslipidemia Drugs Products Offered
12.15.5 Daiichi Sankyo Recent Development
12.16 Eli Lilly
12.16.1 Eli Lilly Dyslipidemia Drugs Corporation Information
12.16.2 Eli Lilly Dyslipidemia Drugs Business Overview and Total Revenue
12.16.3 Eli Lilly Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.16.4 Eli Lilly Dyslipidemia Drugs Products Offered
12.16.5 Eli Lilly Recent Development
12.17 Esperion Therapeutics
12.17.1 Esperion Therapeutics Dyslipidemia Drugs Corporation Information
12.17.2 Esperion Therapeutics Dyslipidemia Drugs Business Overview and Total Revenue
12.17.3 Esperion Therapeutics Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.17.4 Esperion Therapeutics Dyslipidemia Drugs Products Offered
12.17.5 Esperion Therapeutics Recent Development
12.18 GlaxoSmithKline
12.18.1 GlaxoSmithKline Dyslipidemia Drugs Corporation Information
12.18.2 GlaxoSmithKline Dyslipidemia Drugs Business Overview and Total Revenue
12.18.3 GlaxoSmithKline Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.18.4 GlaxoSmithKline Dyslipidemia Drugs Products Offered
12.18.5 GlaxoSmithKline Recent Development
12.19 JW Pharmaceuticals
12.19.1 JW Pharmaceuticals Dyslipidemia Drugs Corporation Information
12.19.2 JW Pharmaceuticals Dyslipidemia Drugs Business Overview and Total Revenue
12.19.3 JW Pharmaceuticals Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.19.4 JW Pharmaceuticals Dyslipidemia Drugs Products Offered
12.19.5 JW Pharmaceuticals Recent Development
12.20 Kadmon Pharmaceuticals
12.20.1 Kadmon Pharmaceuticals Dyslipidemia Drugs Corporation Information
12.20.2 Kadmon Pharmaceuticals Dyslipidemia Drugs Business Overview and Total Revenue
12.20.3 Kadmon Pharmaceuticals Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.20.4 Kadmon Pharmaceuticals Dyslipidemia Drugs Products Offered
12.20.5 Kadmon Pharmaceuticals Recent Development
12.21 Lupin Pharmaceuticals
12.21.1 Lupin Pharmaceuticals Dyslipidemia Drugs Corporation Information
12.21.2 Lupin Pharmaceuticals Dyslipidemia Drugs Business Overview and Total Revenue
12.21.3 Lupin Pharmaceuticals Dyslipidemia Drugs Sales, Revenue and Gross Margin (2015-2020)
12.21.4 Lupin Pharmaceuticals Dyslipidemia Drugs Products Offered
12.21.5 Lupin Pharmaceuticals Recent Development
13 Dyslipidemia Drugs Manufacturing Cost Analysis
13.1 Dyslipidemia Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Dyslipidemia Drugs
13.4 Dyslipidemia Drugs Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Dyslipidemia Drugs Distributors List
14.3 Dyslipidemia Drugs Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Dyslipidemia Drugs Sales (K Units) Growth Rate by Type (2020-2026)
Table 2. Global Dyslipidemia Drugs Sales (K Units) Comparison by Application (2020-2026)
Table 3. Global Market Dyslipidemia Drugs Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Dyslipidemia Drugs Sales (K Units) by Region (2015-2020)
Table 5. Global Dyslipidemia Drugs Sales Market Share by Region (2015-2020)
Table 6. Global Dyslipidemia Drugs Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Dyslipidemia Drugs Revenue Share by Region (2015-2020)
Table 8. Global Dyslipidemia Drugs Sales (K Units) Forecast by Region (2021-2026)
Table 9. Global Dyslipidemia Drugs Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Dyslipidemia Drugs Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Dyslipidemia Drugs Revenue Share Forecast by Region (2021-2026)
Table 12. Global Dyslipidemia Drugs (K Units) of Key Companies (2015-2020)
Table 13. Global Dyslipidemia Drugs Sales Share by Company (2015-2020)
Table 14. Global Dyslipidemia Drugs Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Dyslipidemia Drugs Revenue Share by Company (2015-2020)
Table 16. Global Dyslipidemia Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dyslipidemia Drugs as of 2019)
Table 17. Global Dyslipidemia Drugs Average Price (USD/Unit) of Key Company (2015-2020)
Table 18. Manufacturers Dyslipidemia Drugs Manufacturing Sites and Area Served
Table 19. Manufacturers Dyslipidemia Drugs Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Dyslipidemia Drugs Players
Table 22. Global Dyslipidemia Drugs Sales (K Units) by Type (2015-2020)
Table 23. Global Dyslipidemia Drugs Sales Share by Type (2015-2020)
Table 24. Global Dyslipidemia Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Dyslipidemia Drugs Price (K Units) by Type (2015-2020)
Table 26. Global Dyslipidemia Drugs Sales Share by Type (2021-2026)
Table 27. Global Dyslipidemia Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Dyslipidemia Drugs Revenue Share by Type (2021-2026)
Table 29. Global Dyslipidemia Drugs Price (K Units) by Type (2021-2026)
Table 30. Global Dyslipidemia Drugs Sales (K Units) by Application (2015-2020)
Table 31. Global Dyslipidemia Drugs Sales Share by Application (2015-2020)
Table 32. Global Dyslipidemia Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Dyslipidemia Drugs Price (K Units) by Application (2015-2020)
Table 34. Global Dyslipidemia Drugs Sales (K Units) by Application (2021-2026)
Table 35. Global Dyslipidemia Drugs Sales Share by Application (2021-2026)
Table 36. Global Dyslipidemia Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Dyslipidemia Drugs Revenue Share by Application (2021-2026)
Table 38. Global Dyslipidemia Drugs Price (K Units) by Application (2021-2026)
Table 39. United States Dyslipidemia Drugs Sales (K Units) by Company (2015-2020)
Table 40. United States Dyslipidemia Drugs Sales Market Share by Company (2015-2020)
Table 41. United States Dyslipidemia Drugs Sales (K Units) by Type (2015-2020)
Table 42. United States Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
Table 43. United States Dyslipidemia Drugs Sales (K Units) by Application (2015-2020)
Table 44. United States Dyslipidemia Drugs Sales Market Share by Application (2015-2020)
Table 45. Europe Dyslipidemia Drugs Sales (K Units) by Company (2015-2020)
Table 46. Europe Dyslipidemia Drugs Sales Market Share by Company (2015-2020)
Table 47. Europe Dyslipidemia Drugs Sales (K Units) by Type (2015-2020)
Table 48. Europe Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
Table 49. Europe Dyslipidemia Drugs Sales (K Units) by Application (2015-2020)
Table 50. Europe Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
Table 51. China Dyslipidemia Drugs Sales (K Units) by Company (2015-2020)
Table 52. China Dyslipidemia Drugs Sales Market Share by Company (2015-2020)
Table 53. China Dyslipidemia Drugs Sales (K Units) by Type (2015-2020)
Table 54. China Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
Table 55. China Dyslipidemia Drugs Sales (K Units) by Application (2015-2020)
Table 56. China Dyslipidemia Drugs Sales Market Share by Application (2015-2020)
Table 57. Japan Dyslipidemia Drugs Sales (K Units) by Company (2015-2020)
Table 58. Japan Dyslipidemia Drugs Sales Market Share by Company (2015-2020)
Table 59. Japan Dyslipidemia Drugs Sales (K Units) by Type (2015-2020)
Table 60. Japan Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
Table 61. Japan Dyslipidemia Drugs Sales (K Units) by Application (2015-2020)
Table 62. Japan Dyslipidemia Drugs Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Dyslipidemia Drugs Sales (K Units) by Company (2015-2020)
Table 64. Southeast Asia Dyslipidemia Drugs Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Dyslipidemia Drugs Sales (K Units) by Type (2015-2020)
Table 66. Southeast Asia Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Dyslipidemia Drugs Sales (K Units) by Type (2015-2020)
Table 68. Southeast Asia Dyslipidemia Drugs Sales Market Share by Application (2015-2020)
Table 69. India Dyslipidemia Drugs Sales (K Units) by Company (2015-2020)
Table 70. India Dyslipidemia Drugs Sales Market Share by Company (2015-2020)
Table 71. India Dyslipidemia Drugs Sales (K Units) by Type (2015-2020)
Table 72. India Dyslipidemia Drugs Sales Market Share by Type (2015-2020)
Table 73. India Dyslipidemia Drugs Sales (K Units) by Application (2015-2020)
Table 74. India Dyslipidemia Drugs Sales Market Share by Application (2015-2020)
Table 75. AstraZeneca Corporation Information
Table 76. AstraZeneca Description and Business Overview
Table 77. AstraZeneca Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. AstraZeneca Dyslipidemia Drugs Product
Table 79. AstraZeneca Recent Development
Table 80. Merck Corporation Information
Table 81. Merck Description and Business Overview
Table 82. Merck Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Merck Dyslipidemia Drugs Product
Table 84. Merck Recent Development
Table 85. Pfizer Corporation Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Pfizer Dyslipidemia Drugs Product
Table 89. Pfizer Recent Development
Table 90. Sanofi Corporation Information
Table 91. Sanofi Description and Business Overview
Table 92. Sanofi Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Sanofi Dyslipidemia Drugs Product
Table 94. Sanofi Recent Development
Table 95. Alnylam Pharmaceuticals Corporation Information
Table 96. Alnylam Pharmaceuticals Description and Business Overview
Table 97. Alnylam Pharmaceuticals Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. Alnylam Pharmaceuticals Dyslipidemia Drugs Product
Table 99. Alnylam Pharmaceuticals Recent Development
Table 100. Amarin Corporation Corporation Information
Table 101. Amarin Corporation Description and Business Overview
Table 102. Amarin Corporation Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. Amarin Corporation Dyslipidemia Drugs Product
Table 104. Amarin Corporation Recent Development
Table 105. Amgen Corporation Information
Table 106. Amgen Description and Business Overview
Table 107. Amgen Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Amgen Dyslipidemia Drugs Product
Table 109. Amgen Recent Development
Table 110. Bristol-Myers Squibb Corporation Information
Table 111. Bristol-Myers Squibb Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 112. Bristol-Myers Squibb Description and Business Overview
Table 113. Bristol-Myers Squibb Dyslipidemia Drugs Product
Table 114. Bristol-Myers Squibb Recent Development
Table 115. Catabasis Pharmaceuticals Corporation Information
Table 116. Catabasis Pharmaceuticals Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 117. Catabasis Pharmaceuticals Description and Business Overview
Table 118. Catabasis Pharmaceuticals Dyslipidemia Drugs Product
Table 119. Catabasis Pharmaceuticals Recent Development
Table 120. Cerenis Corporation Information
Table 121. Cerenis Description and Business Overview
Table 122. Cerenis Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 123. Cerenis Dyslipidemia Drugs Product
Table 124. Cerenis Recent Development
Table 125. Cipla Corporation Information
Table 126. Cipla Description and Business Overview
Table 127. Cipla Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 128. Cipla Dyslipidemia Drugs Product
Table 129. Cipla Recent Development
Table 130. CJ HealthCare Corporation Information
Table 131. CJ HealthCare Description and Business Overview
Table 132. CJ HealthCare Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 133. CJ HealthCare Dyslipidemia Drugs Product
Table 134. CJ HealthCare Recent Development
Table 135. CKD Bio Corporation Information
Table 136. CKD Bio Description and Business Overview
Table 137. CKD Bio Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 138. CKD Bio Dyslipidemia Drugs Product
Table 139. CKD Bio Recent Development
Table 140. Daewoong Pharmaceutical Corporation Information
Table 141. Daewoong Pharmaceutical Description and Business Overview
Table 142. Daewoong Pharmaceutical Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 143. Daewoong Pharmaceutical Dyslipidemia Drugs Product
Table 144. Daewoong Pharmaceutical Recent Development
Table 145. Daiichi Sankyo Corporation Information
Table 146. Daiichi Sankyo Description and Business Overview
Table 147. Daiichi Sankyo Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 148. Daiichi Sankyo Dyslipidemia Drugs Product
Table 149. Daiichi Sankyo Recent Development
Table 150. Eli Lilly Corporation Information
Table 151. Eli Lilly Description and Business Overview
Table 152. Eli Lilly Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 153. Eli Lilly Dyslipidemia Drugs Product
Table 154. Eli Lilly Recent Development
Table 155. Esperion Therapeutics Corporation Information
Table 156. Esperion Therapeutics Description and Business Overview
Table 157. Esperion Therapeutics Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 158. Esperion Therapeutics Dyslipidemia Drugs Product
Table 159. Esperion Therapeutics Recent Development
Table 160. GlaxoSmithKline Corporation Information
Table 161. GlaxoSmithKline Description and Business Overview
Table 162. GlaxoSmithKline Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 163. GlaxoSmithKline Dyslipidemia Drugs Product
Table 164. GlaxoSmithKline Recent Development
Table 165. JW Pharmaceuticals Corporation Information
Table 166. JW Pharmaceuticals Description and Business Overview
Table 167. JW Pharmaceuticals Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 168. JW Pharmaceuticals Dyslipidemia Drugs Product
Table 169. JW Pharmaceuticals Recent Development
Table 170. Kadmon Pharmaceuticals Corporation Information
Table 171. Kadmon Pharmaceuticals Description and Business Overview
Table 172. Kadmon Pharmaceuticals Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 173. Kadmon Pharmaceuticals Dyslipidemia Drugs Product
Table 174. Kadmon Pharmaceuticals Recent Development
Table 175. Lupin Pharmaceuticals Corporation Information
Table 176. Lupin Pharmaceuticals Description and Business Overview
Table 177. Lupin Pharmaceuticals Dyslipidemia Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 178. Lupin Pharmaceuticals Dyslipidemia Drugs Product
Table 179. Lupin Pharmaceuticals Recent Development
Table 180. Production Base and Market Concentration Rate of Raw Material
Table 181. Key Suppliers of Raw Materials
Table 182. Dyslipidemia Drugs Distributors List
Table 183. Dyslipidemia Drugs Customers List
Table 184. Market Key Trends
Table 185. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 186. Key Challenges
Table 187. Research Programs/Design for This Report
Table 188. Key Data Information from Secondary Sources
Table 189. Key Data Information from Primary Sources
List of Figures
Figure 1. Dyslipidemia Drugs Product Picture
Figure 2. Global Dyslipidemia Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Dyslipidemia Drugs Market Share by Application in 2020 & 2026
Figure 6. Hospitals and Clinics Examples
Figure 7. Medical Laboratories Examples
Figure 8. Drug Stores Examples
Figure 9. Others Examples
Figure 10. Global Dyslipidemia Drugs Sales (K Units) Growth Rate (2015-2026)
Figure 11. Global Dyslipidemia Drugs Revenue (US$ Million) Growth Rate (2015-2026)
Figure 12. Global Dyslipidemia Drugs Price Trends Growth Rate (2015-2026) (USD/Unit)
Figure 13. Global Dyslipidemia Drugs Revenue Market Share by Region: 2015 VS 2020
Figure 14. Global Dyslipidemia Drugs Revenue Market Share by Region: 2021 VS 2026
Figure 15. United States Dyslipidemia Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 16. United States Dyslipidemia Drugs Sales (K Units) Growth Rate (2015-2026)
Figure 17. Europe Dyslipidemia Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 18. Europe Dyslipidemia Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 19. China Dyslipidemia Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 20. China Dyslipidemia Drugs Sales (Million USD) and Growth Rate (2015-2026)
Figure 21. Japan Dyslipidemia Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 22. Japan Dyslipidemia Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Dyslipidemia Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 24. Southeast Asia Dyslipidemia Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 25. India Dyslipidemia Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 26. India Dyslipidemia Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 27. Global 5 Largest Dyslipidemia Drugs Players Market Share by Revenue in Dyslipidemia Drugs 2015 & 2019
Figure 28. Dyslipidemia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 29. Global Dyslipidemia Drugs Revenue Share by Type (2015-2020)
Figure 30. Global Dyslipidemia Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 31. Global Dyslipidemia Drugs Revenue Share by Application (2015-2020)
Figure 32. Global Dyslipidemia Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 33. United States Dyslipidemia Drugs Sales Market Share by Type in 2019
Figure 34. United States Dyslipidemia Drugs Sales Market Share by Type in 2019
Figure 35. Europe Dyslipidemia Drugs Sales Market Share by Company in 2019
Figure 36. Europe Dyslipidemia Drugs Sales Market Share by Type in 2019
Figure 37. Europe Dyslipidemia Drugs Sales Market Share by Application in 2019
Figure 38. China Dyslipidemia Drugs Sales Market Share by Company in 2019
Figure 39. China Dyslipidemia Drugs Sales Market Share by Type in 2019
Figure 40. China Dyslipidemia Drugs Sales Market Share by Application in 2019
Figure 41. Japan Dyslipidemia Drugs Sales Market Share by Company in 2019
Figure 42. Japan Dyslipidemia Drugs Sales Market Share by Type in 2019
Figure 43. Japan Dyslipidemia Drugs Sales Market Share by Application in 2019
Figure 44. Southeast Asia Dyslipidemia Drugs Sales Market Share by Company in 2019
Figure 45. Southeast Asia Dyslipidemia Drugs Sales Market Share by Type in 2019
Figure 46. Southeast Asia Dyslipidemia Drugs Sales Market Share by Application in 2019
Figure 47. India Dyslipidemia Drugs Sales Market Share by Company in 2019
Figure 48. India Dyslipidemia Drugs Sales Market Share by Type in 2019
Figure 49. India Dyslipidemia Drugs Sales Market Share by Application in 2019
Figure 50. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Alnylam Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Amarin Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Catabasis Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Cerenis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Cipla Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. CJ HealthCare Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. CKD Bio Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Daewoong Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Daiichi Sankyo Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Esperion Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. JW Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 69. Kadmon Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 70. Lupin Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 71. Key Raw Materials Price Trend
Figure 72. Manufacturing Cost Structure of Dyslipidemia Drugs
Figure 73. Manufacturing Process Analysis of Dyslipidemia Drugs
Figure 74. Dyslipidemia Drugs Industrial Chain Analysis
Figure 75. Channels of Distribution
Figure 76. Distributors Profiles
Figure 77. Porter's Five Forces Analysis
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed
コレステロール低下薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Cholesterol-Lowering Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 2.7% in the forecast period of 2020 to 2025 and will expected to reach USD 19930 million by 2025, from USD 17940 million in 2019. The Cholesterol…- 内分泌系薬の世界市場レポート2020 Market Analysis and Insights: Global Endocrine System Drugs Market The global Endocrine System Drugs market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global Endocrine System Drugs Scope and Market Size The global…
- エクセナチド薬の世界市場レポート2020 A recently published report by QY Research titled Global Exenatide Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate da…
- 無菌注射薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Sterile Injectable Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.0% in the forecast period of 2020 to 2025 and will expected to reach USD 4258.5 million by 2025, from USD 3506.7 million in 2019. The Sterile Inj…
- 消化器系薬の世界市場レポート2020 Market Analysis and Insights: Global Digestive System Drugs Market The global Digestive System Drugs market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global Digestive System Drugs Scope and Market Size The global…